Retatrutide Regulatory Status
Retatrutide is not approved for routine clinical use in any country worldwide—it remains an investigational drug currently undergoing Phase III clinical trials. 1, 2, 3
Current Development Status
Phase III trials began on August 28,2023 for type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity, but no regulatory approvals have been granted in any jurisdiction. 3
The drug is mentioned in the 2024 EASL-EASD-EASO guidelines only as an investigational agent being developed alongside other dual and triple agonists (e.g., tirzepatide, cotadutide, survodutide), with no histology data yet available for these newer compounds. 1
Retatrutide is described as a triple GLP-1-GIP-glucagon agonist in development for metabolic dysfunction-associated steatotic liver disease (MASLD), but it has not progressed beyond clinical trial phases. 1
Evidence Base
Phase II data demonstrated mean weight loss of 17.5% at 24 weeks and 24.4% at 48 weeks in adults with obesity, but these results have not translated into regulatory approval. 3
In type 2 diabetes, Phase II trials showed 16.9% weight loss and 2.2% HbA1c reduction after 36 weeks, with 82% of participants achieving HbA1c ≤6.5%. 4
The safety profile mirrors other GLP-1 receptor agonists, with gastrointestinal symptoms (nausea, diarrhea, vomiting) being the most common adverse events. 2, 5
Access Limitations
No country has granted marketing authorization for retatrutide—it is available exclusively through clinical trial enrollment. 3, 4
The comprehensive Phase III program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes before any regulatory submissions can occur. 4
Unlike approved agents such as semaglutide (approved for obesity) or tirzepatide (approved for both type 2 diabetes and obesity), retatrutide lacks FDA, EMA, or any other regulatory body approval. 1, 5
Clinical Context
The 2024 EASL-EASD-EASO guidelines explicitly state there is insufficient evidence to support using retatrutide as a MASH-targeted therapy, reinforcing its investigational status. 1
Head-to-head comparator studies between retatrutide and approved weight loss medications (semaglutide, tirzepatide) are notably absent from the development pipeline, which represents a significant gap in establishing its clinical positioning. 2, 6